BibTex RIS Cite

Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient

Year 2010, , 138 - 140, 01.06.2010
https://doi.org/10.5799/ahinjs.01.2010.02.0029

Abstract

References

  • Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006;240–5.
  • James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–8.
  • Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycthemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274–81.
  • Jelinek J, Oki Y, Gharibyan V et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370–3.
  • Bock O, Büsche G, Koop C, Schröter S, Buhr T, Kreipe H. Detection of the single hotspot mutation in the JH2 pseudokinase domain of janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. Journal of Molecular Diagnostics 2006; 8:170-7.
  • Krämer A. JAK2-V617F and BCR-ABL-double Jeopardy? Leukemia Res 2008;32:1489–90.
  • Pardini S, Fozza C, Contini S et al. A case of coexistence between JAK2V617F and BCR/ABL. Eur J Hematol 2008; 81.75–6.
  • Inami M, Inokuchi K, Okabe M et al. Polycthemia associated with the JAK2V617F mutation emerged during treatment of chronic mylogeneous leukemia. Leukemia 2007;21:1103–4.
  • Cambier N, Renneville A, Cazaentre T et al. JAK2V617Fpositive polycythemia vera and philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008;22:1454–5.
  • Hussein K, Bock O, Seegers E et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disorder with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007;109:4106–7.
  • Krämer A, Reiter A, Kruth J et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukemia. Lancet 2007;8:658–60.
  • Veronese L, Tchirkov A, Richard-Pebrel C et al. A thrombocytosis occuring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm. Leuk Res 2010;34:94–6.
  • Campiotti L, Appio L, Solbiati F, AgenoW, Venco A. JAK2V617F mutation and Philadelphia positive chronic myeloid leukemia. Leukemia Research 2009; 33.212–3.
  • Jallades L, Hateyye S, Tigaud I et al. Emergence of therapy-unrelated CML on a backgraund of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008;32:1608–10.
  • Bornhäuser M, Mohr B, Oelschlaegel U et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007; 21:1824–6.
  • Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005;128:730–6.

Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient

Year 2010, , 138 - 140, 01.06.2010
https://doi.org/10.5799/ahinjs.01.2010.02.0029

Abstract

liland DG. Expression of Jak2V617F causes a polycthemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274–81. 4. Jelinek J, Oki Y, Gharibyan V et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Phil- adelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370–3

References

  • Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006;240–5.
  • James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–8.
  • Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycthemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274–81.
  • Jelinek J, Oki Y, Gharibyan V et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370–3.
  • Bock O, Büsche G, Koop C, Schröter S, Buhr T, Kreipe H. Detection of the single hotspot mutation in the JH2 pseudokinase domain of janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. Journal of Molecular Diagnostics 2006; 8:170-7.
  • Krämer A. JAK2-V617F and BCR-ABL-double Jeopardy? Leukemia Res 2008;32:1489–90.
  • Pardini S, Fozza C, Contini S et al. A case of coexistence between JAK2V617F and BCR/ABL. Eur J Hematol 2008; 81.75–6.
  • Inami M, Inokuchi K, Okabe M et al. Polycthemia associated with the JAK2V617F mutation emerged during treatment of chronic mylogeneous leukemia. Leukemia 2007;21:1103–4.
  • Cambier N, Renneville A, Cazaentre T et al. JAK2V617Fpositive polycythemia vera and philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008;22:1454–5.
  • Hussein K, Bock O, Seegers E et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disorder with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007;109:4106–7.
  • Krämer A, Reiter A, Kruth J et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukemia. Lancet 2007;8:658–60.
  • Veronese L, Tchirkov A, Richard-Pebrel C et al. A thrombocytosis occuring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm. Leuk Res 2010;34:94–6.
  • Campiotti L, Appio L, Solbiati F, AgenoW, Venco A. JAK2V617F mutation and Philadelphia positive chronic myeloid leukemia. Leukemia Research 2009; 33.212–3.
  • Jallades L, Hateyye S, Tigaud I et al. Emergence of therapy-unrelated CML on a backgraund of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res 2008;32:1608–10.
  • Bornhäuser M, Mohr B, Oelschlaegel U et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 2007; 21:1824–6.
  • Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005;128:730–6.
There are 16 citations in total.

Details

Primary Language Turkish
Journal Section Letter to the Editor
Authors

Osman Yokuş This is me

Fatih Kurnaz This is me

Özlem Şahin Balçık This is me

Burak Uz This is me

Murat Albayrak This is me

Publication Date June 1, 2010
Published in Issue Year 2010

Cite

APA Yokuş, O., Kurnaz, F., Balçık, Ö. Ş., Uz, B., et al. (2010). Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient. Journal of Clinical and Experimental Investigations, 1(2), 138-140. https://doi.org/10.5799/ahinjs.01.2010.02.0029
AMA Yokuş O, Kurnaz F, Balçık ÖŞ, Uz B, Albayrak M. Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient. J Clin Exp Invest. June 2010;1(2):138-140. doi:10.5799/ahinjs.01.2010.02.0029
Chicago Yokuş, Osman, Fatih Kurnaz, Özlem Şahin Balçık, Burak Uz, and Murat Albayrak. “Coexistance of JAK2V617F Mutation and BCR/ABL Translocation in One Patient”. Journal of Clinical and Experimental Investigations 1, no. 2 (June 2010): 138-40. https://doi.org/10.5799/ahinjs.01.2010.02.0029.
EndNote Yokuş O, Kurnaz F, Balçık ÖŞ, Uz B, Albayrak M (June 1, 2010) Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient. Journal of Clinical and Experimental Investigations 1 2 138–140.
IEEE O. Yokuş, F. Kurnaz, Ö. Ş. Balçık, B. Uz, and M. Albayrak, “Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient”, J Clin Exp Invest, vol. 1, no. 2, pp. 138–140, 2010, doi: 10.5799/ahinjs.01.2010.02.0029.
ISNAD Yokuş, Osman et al. “Coexistance of JAK2V617F Mutation and BCR/ABL Translocation in One Patient”. Journal of Clinical and Experimental Investigations 1/2 (June 2010), 138-140. https://doi.org/10.5799/ahinjs.01.2010.02.0029.
JAMA Yokuş O, Kurnaz F, Balçık ÖŞ, Uz B, Albayrak M. Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient. J Clin Exp Invest. 2010;1:138–140.
MLA Yokuş, Osman et al. “Coexistance of JAK2V617F Mutation and BCR/ABL Translocation in One Patient”. Journal of Clinical and Experimental Investigations, vol. 1, no. 2, 2010, pp. 138-40, doi:10.5799/ahinjs.01.2010.02.0029.
Vancouver Yokuş O, Kurnaz F, Balçık ÖŞ, Uz B, Albayrak M. Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient. J Clin Exp Invest. 2010;1(2):138-40.